IDO1 Inhibitors Targeting Apoprotein for Potent Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of indoleamine 2,3-dioxygenase (IDO1, IDO2, and tryptophan dioxygenase (TDO) lack high potency and selectivity, and their in vivo pharmacokinetic properties are suboptimal, particularly in treating cancers and immune-related disorders.
Innovation Solution
Development of a family of compounds characterized by specific chemical formulas that inhibit IDO1, IDO2, and TDO, targeting the apoprotein before heme cofactor incorporation, offering potential advantages over direct heme-binding inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current IDO1/IDO2/TDO inhibitors are used, then immune response modulation is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features tailored to bind selectively to IDO1's heme pocket. The compounds contain nitrogen-containing heterocyclic rings and aromatic substituents that form specific interactions with key residues in the IDO1 active site, achieving high potency (IC50 < 200 nM) and selectivity for IDO1 over IDO2 and TDO enzymes.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the inhibitor molecules, including the type of nitrogen-containing heterocycle, position and nature of aromatic substituents, and linker chain length. These parameter optimizations enable fine-tuning of binding affinity and selectivity, resulting in compounds with IC50 values less than 200 nM for IDO1.
2Reliability
If current IDO1/IDO2/TDO inhibitors are used, then enzyme inhibition is achieved, but in vivo pharmacokinetic properties are suboptimal
Solution Approach 1:
The patent applies parameter changes by modifying physicochemical parameters of the inhibitor molecules, including molecular weight, lipophilicity (logP), and hydrogen bonding capacity. These modifications improve oral bioavailability, plasma protein binding, and tissue distribution while maintaining potent enzyme inhibition, thereby optimizing in vivo pharmacokinetic properties.
3Reliability
If heme-binding inhibitors are used, then direct enzyme inhibition is achieved, but the patent targets apoprotein before heme cofactor incorporation
Solution Approach 1:
The patent applies preliminary action by designing inhibitors that bind to the apoprotein form of IDO1 before heme cofactor incorporation. This preliminary binding prevents heme incorporation and stabilizes the apoprotein, thereby inhibiting enzyme activity. This mechanism differs from conventional heme-binding inhibitors and provides a novel therapeutic approach with potential advantages in selectivity and efficacy.
Data Source
AI summary
Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.